FDA Concludes Investigation of Cyclospora Outbreak Linked to Lettuce
By Josh Beckerman
The Food and Drug Administration concluded its investigation of a cyclospora outbreak linked to iceberg lettuce and discussed prevention plans for 2027.
The Centers for Disease Control and Prevention declared the outbreak over on Sept. 11 and said cases totaled 12,883, including 570 hospitalizations. Health officials linked the outbreak to Taylor Farms lettuce grown in Mexico. Thousands of additional 2026 cases weren't part of that outbreak.
While "there is currently not enough evidence to conclusively determine how contamination occurred in this outbreak," positive samples show that cyclospora was present in the environment where lettuce was grown and processed, the FDA said.
Genotyping of both positive environmental samples collected during onsite inspections has been completed. The FDA said it is continuing its analysis to determine how sample results relate to ongoing genotyping of clinical specimens.
"In advance of the 2027 growing and harvesting season, the FDA will increase activities focused on surveillance, outreach, and finding innovative solutions to prevent Cyclospora contamination of fresh produce," the agency said.
Plans include enhancing laboratory capacity in Mexico and using new and alternative data sources and tools to monitor factors such as weather events that may lead to cyclospora spread.
The efforts also include working with the CDC to enhance and align genotyping methods for cyclospora, to create a single, replicable standard within the federal government, with partner nations and in the industry to help improve the tracing of outbreaks to their sources.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 02, 2026 16:15 ET (20:15 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
